Literature DB >> 616067

Kinetics of ethanol inhibition of galactose elimination in perfused pig liver.

S Keiding, S Johansen, K Tønnesen.   

Abstract

The effect of ethanol (5--25 mM) on the galactose elimination kinetics in the intact liver was studied in the isolated perfused pig liver, using the steady-state infusion technique. Ethanol reduced galactose-Vmax on average to 0.07 mmol/min kg liver in six experiments from 0.43 mmol/min kg obtained in control experiments without ethanol. Also Km was significantly reduced from 0.23 mmol/l plasma water to 0.03 mmol/l. Ethanol increased UDP-galactose ten-fold simultaneous with a rise in hepatic outflow ratio of lactate to pyruvate to about 300 from 10; this indicates that ethanol inhibits epimerase. In experiments with increasing galactose elimination rates, the concentration of galactose-1-P increased much less than the concentration of galactose, and the phosphorylation of galactose therefore seems to be rate-limiting. In vitro galactokinase is inhibited by galactose-1-P. In the present study ethanol increased galactose-1-P five to ten times, and the reduction of Vmax and Km by ethanol could be explained by uncompetitive inhibition by galactose-1-P with Ki about 0.1 mmol/l. Ethanol decreased UDP-glucose to about 40% and UTP to less than 5%, probably due to trapping as UDP-galactose. This may depress the forward transferase reaction, and therefore the other co-substrate galactose-1-P rises--and inhibits galactokinase.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 616067     DOI: 10.3109/00365517709101836

Source DB:  PubMed          Journal:  Scand J Clin Lab Invest        ISSN: 0036-5513            Impact factor:   1.713


  4 in total

1.  Preoperative galactose elimination capacity predicts complications and survival after hepatic resection.

Authors:  Claudio A Redaelli; Jean-François Dufour; Markus Wagner; Martin Schilling; Jürg Hüsler; Lukas Krähenbühl; Markus W Büchler; Jürg Reichen
Journal:  Ann Surg       Date:  2002-01       Impact factor: 12.969

2.  Treatment of liver disease with malotilate. A pharmacokinetic and pharmacodynamic phase II study in cirrhosis.

Authors:  M Bührer; J Y Le Cotonnec; M Wermeille; J Bircher
Journal:  Eur J Clin Pharmacol       Date:  1986       Impact factor: 2.953

3.  Hepatic uptake and metabolism of galactose can be quantified in vivo by 2-[18F]fluoro-2-deoxygalactose positron emission tomography.

Authors:  Michael Sørensen; Ole Lajord Munk; Frank Viborg Mortensen; Aage Kristian Olsen; Dirk Bender; Ludvik Bass; Susanne Keiding
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2008-05-15       Impact factor: 4.052

4.  [Tryptophan loading test as a function parameter in liver diseases].

Authors:  M Rössle; R Herz; W Hiss; W Gerok
Journal:  Klin Wochenschr       Date:  1983-03-15
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.